胸腺肽α1联合阿帕替尼治疗晚期非小细胞肺癌的疗效及对患者免疫功能及生活质量的影响  

Effect of thymopeptide α1 combined with apatinib in the treatment of advanced non-small cell lung cancer and its effect on immune function and quality of life

作　　者：马敬涛 陈霖 熊晓英 MA Jingtao;CHEN Lin;XIONG Xiaoying(Department of Pharmacy,Chongqing Liangjiang New Area Traditional Chinese Medicine Hospital,Chongqing 401123,China)

机构地区：[1]重庆两江新区中医院药剂科,重庆401123

出　　处：《癌症进展》2025年第1期59-62,共4页Oncology Progress

摘　　要：目的探讨胸腺肽α1联合阿帕替尼治疗晚期非小细胞肺癌(NSCLC)的疗效及对患者免疫功能及生活质量的影响。方法依据治疗方法的不同将60例晚期NSCLC患者分为对照组(n=29)和联合组(n=31),对照组患者接受阿帕替尼治疗,联合组患者接受胸腺肽α1联合阿帕替尼治疗。比较两组患者的临床疗效、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+)和CD4^(+)/CD8^(+))、生活质量[卡氏功能状态(KPS)、肺癌患者生命质量测定量表(FACT-L)]和不良反应发生情况。结果联合组患者的客观缓解率(ORR)为58.06%,高于对照组患者的20.69%,疾病控制率(DCR)为80.65%,高于对照组患者的51.72%,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均高于本组治疗前,CD8^(+)水平均低于本组治疗前,联合组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者KPS、FACT-L评分均高于本组治疗前,联合组患者KPS、FACT-L评分均高于对照组,差异均有统计学意义(P﹤0.05)。联合组患者的不良反应总发生率为12.90%,低于对照组患者的41.38%,差异有统计学意义(P﹤0.05)。结论胸腺肽α1联合阿帕替尼治疗晚期NSCLC患者可明显提高临床疗效,改善患者的免疫功能和生活质量,降低不良反应发生率。Objective To investigate effect of thymopeptideα1 combined with apatinib in the treatment of advanced non-small cell lung cancer(NSCLC)and its effect on immune function and quality of life.Method According to different treatment methods,60 patients with advanced NSCLC were divided into control group(n=29)and combination group(n=31).Patients in the control group received apatinib treatment,while patients in the combination group received thymopeptideα1 combined with apatinib treatment.The clinical efficacy,immune function indexes(CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)),quality of life[Karnofsky performance status(KPS),functional assessment of cancer therapy-lung(FACT-L)],and incidence of adverse reactions were compared between the two groups.Result The objective response rate(ORR)in combination group was 58.06%,which was higher than 20.69%in control group,and the disease control rate(DCR)was 80.65%,which was higher than 51.72%in control group,and the differences were statistically significant(P<0.05).After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in both groups were higher than those before treatment,while the levels of CD8^(+)were lower than those before treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in combination group were higher than those in control group,while the level of CD8^(+)was lower than that in control group,and the differences were statistically significant(P<0.05).After treatment,the KPS and FACT-L scores in both groups were higher than those before treatment,and the KPS and FACT-L scores in combination group were higher than those in control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in combination group was 12.90%,which was lower than 41.38%in control group,and the difference was statistically significant(P<0.05).Conclusion Thymopeptideα1 combined with apatinib in the treatment of advanced NSCLC patients can significantly improve clinical efficacy,enhance immune function and quality of life,and redu

关 键 词：胸腺肽Α1 阿帕替尼 非小细胞肺癌 免疫功能 生活质量 

分 类 号：R734.2[医药卫生—肿瘤]